Monitoring neoadjuvanter Chemotherapie

Monitoring Response to neo-adjuvant chemotherapy Assessment of the change in tumour burden is an important feature of the clinical evaluation of cancer therapeutics. Tumour shrinkage and time to the development of disease progression are important end-points in cancer clinical trials. However, these end-points are useful only if based on widely accepted and readily applied standard criteria. Criteria, known as RECIST, were published and are updated on a regular base. The revised RECIST includes a new imaging appendix and underlines the importance to move from anatomic unidimensional assessment to either volumetr…